NysnoBio

NysnoBio is a private, preclinical-stage biotech developing a novel gene therapy platform centered on the Parkin enzyme, a key regulator of mitochondrial health. The company's lead program targets Parkin-associated Parkinson's disease (PARKIN-PD), a genetically defined subset with high penetrance, with the goal of delivering a one-time, disease-modifying treatment. Leveraging deep scientific expertise in Parkin biology and AAV gene therapy, NysnoBio is positioned to address a significant unmet need in neurodegenerative diseases and potentially expand to broader idiopathic Parkinson's populations. The company is currently in IND-enabling studies.

AAV-based gene therapy platform focused on delivering the Parkin enzyme to restore mitochondrial quality control via mitophagy in neurons.

NysnoBio competes in the broad Parkinson's disease therapeutic space, which includes symptomatic treatments and numerous disease-modifying approaches targeting alpha-synuclein, inflammation, and other pathways. Its specific focus on Parkin gene replacement via AAV is a unique, precision medicine angle, but it must compete for funding, patient recruitment, and ultimately market share against larger, more diversified players.